Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:AIM NYSEARCA:SDY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$0.31-12.2%$0.44$0.21▼$20.35$4.55M1.1829.36 million shs2.07 million shsSDYSPDR S&P Dividend ETF$153.11+0.6%$149.32$134.75▼$156.39$22.41B0.69262,427 shs173,601 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech0.00%-17.85%-28.42%-55.41%-96.50%SDYSPDR S&P Dividend ETF0.00%+1.73%+2.15%+6.02%+14.29%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$0.31-12.2%$0.44$0.21▼$20.35$4.55M1.1829.36 million shs2.07 million shsSDYSPDR S&P Dividend ETF$153.11+0.6%$149.32$134.75▼$156.39$22.41B0.69262,427 shs173,601 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech0.00%-17.85%-28.42%-55.41%-96.50%SDYSPDR S&P Dividend ETF0.00%+1.73%+2.15%+6.02%+14.29%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMAIM ImmunoTech 3.00Buy$9.002,783.69% UpsideSDYSPDR S&P Dividend ETF 2.42Hold$153.11N/ACurrent Analyst Ratings BreakdownLatest SDY, RPS, DWF, MNZS, and AIM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026AIMAIM ImmunoTech Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $9.00(Data available from 6/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMAIM ImmunoTech$90K50.49N/AN/A($2.99) per share-0.10SDYSPDR S&P Dividend ETFN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMAIM ImmunoTech-$13.96M-$24.68N/AN/AN/A-14,123.40%N/A-177.72%N/ASDYSPDR S&P Dividend ETFN/AN/A19.85N/AN/AN/AN/AN/AN/ALatest SDY, RPS, DWF, MNZS, and AIM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026AIMAIM ImmunoTechN/A-$0.69N/A-$0.69N/A$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAIMAIM ImmunoTechN/AN/AN/AN/AN/ASDYSPDR S&P Dividend ETF$3.732.44%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMAIM ImmunoTech0.101.011.01SDYSPDR S&P Dividend ETFN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMAIM ImmunoTech12.02%SDYSPDR S&P Dividend ETF43.42%Insider OwnershipCompanyInsider OwnershipAIMAIM ImmunoTech0.95%SDYSPDR S&P Dividend ETFN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMAIM ImmunoTech2014.56 million14.43 millionNot OptionableSDYSPDR S&P Dividend ETFN/A146.35 millionN/ANot OptionableSDY, RPS, DWF, MNZS, and AIM HeadlinesRecent News About These CompaniesSPDR S&P dividend ETF declares quarterly distribution of $0.9680June 23, 2026 | msn.comShould State Street SPDR S&P Dividend ETF (SDY) Be on Your Investing Radar?June 16, 2026 | zacks.comGuide to Dividend Aristocrat ETF InvestingJune 12, 2026 | zacks.comIs State Street SPDR S&P Dividend ETF (SDY) a Strong ETF Right Now?June 10, 2026 | zacks.comTop ETFs to Ride the Target & Lowe's Earnings SurgeMay 20, 2026 | etftrends.comEThree Dividend ETFs Built to Survive Every Recession and Pay You Through ItMay 19, 2026 | 247wallst.comDividend ETF ideas for steady long-term incomeMay 13, 2026 | msn.comKiplinger highlights high-yield dividend ETFs amid narrowing rallyMay 12, 2026 | msn.comKiplinger highlights top dividend ETFs and mutual funds for 2026May 6, 2026 | msn.comDividend growth ETFs gain spotlight amid market shiftMay 5, 2026 | msn.comSDY: Blame Negative Alpha On Defensive Dividend AristocratsApril 20, 2026 | seekingalpha.comShould State Street SPDR S&P Dividend ETF (SDY) Be on Your Investing Radar?April 15, 2026 | zacks.comIs State Street SPDR S&P Dividend ETF (SDY) a Strong ETF Right Now?April 10, 2026 | zacks.comSPDR S&P Dividend ETF declares quarterly distribution of $0.8743March 23, 2026 | msn.comThe Zacks Analyst Blog SDY, NOBL, OUSA and PFMMarch 12, 2026 | zacks.comPlay Dividend Growth ETFs With a Long-Term ViewMarch 11, 2026 | zacks.comState Street® SPDR® S&P® Global Dividend ETFMarch 4, 2026 | markets.businessinsider.comShield & Yield: Navigate 2026's Volatility With This Dividend ETFFebruary 27, 2026 | etftrends.comEGot $10,000? Put It in These Dividend ETFs NowFebruary 27, 2026 | 247wallst.comRetirees Rely On These 5 Safe High Yield Monthly Pay Dividend StocksFebruary 19, 2026 | 247wallst.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSDY, RPS, DWF, MNZS, and AIM Company DescriptionsAIM ImmunoTech NYSEAMERICAN:AIM$0.31 -0.04 (-12.18%) Closing price 06/26/2026 04:10 PM EasternExtended Trading$0.31 0.00 (-0.03%) As of 06/26/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.SPDR S&P Dividend ETF NYSEARCA:SDY$153.11 +0.96 (+0.63%) As of 06/26/2026 04:10 PM EasternThe SPDR S&P Dividend ETF seeks to closely match the returns and characteristics of the S&P High Yield Dividend Aristocrats Index (the Index). The Index is designed to measure the performance of the 60 highest dividend yielding S&P Composite 1500 Index constituents that have followed a managed-dividends policy of consistently increasing dividends every year for at least 25 consecutive years. The Fund generally invests substantially all, but at least 80%, of its total assets in the securities comprising the Index. In addition, the Fund may invest in equity securities that are not included in the Index, cash and cash equivalents or money market instruments, such as repurchase agreements and money market funds (including money market funds advised by the Adviser). SSgA Funds Management, Inc. is the investment adviser to the Fund. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/22 - 06/26 Rocket Lab's NASA Win Tests Key Support After Sharp Pullback 3 ETFs Pairing Market-Beating Returns With High Dividend Yields BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone SpaceX Has Real Value—But These 3 Stocks Have Better Odds Right Now Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout 3 Stocks That Could Benefit as the Robotaxi Race Heats Up Palantir’s Valuation Problem Just Met 2 New Growth Catalysts Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
